Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
-, PARACETAMOL , CILAZAPRIL , Dapirolizumab pegol, EPINEPHRINE , DIPHENHYDRAMINE , -, -, -, -, -, -, -
Lacuna Pharma Pty Ltd
Systemic lupus erythematosus (SLE)
1 trial -
-, Rozanolixizumab
Lacuna Pharma Pty Ltd
Generalized Myasthenia Gravis
1 trial -
-, Rozanolixizumab
Lacuna Pharma Pty Ltd
Generalized Myasthenia Gravis
1 trial -
A 52-Week, Open-Label Extension Study of ACP-204 in Adults with Alzheimer's Disease Psychosis
Lacuna Pharma Pty Ltd
Alzheimer's Disease Psychosis
1 trial -
A 52-Week, Phase 3, Open-Label Extension Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)
Lacuna Pharma Pty Ltd
Lewy body Dementia psychosis (LBDP)
1 trial -
ABIRATERONE, 177Lu-PNT2002, GALLIUM (68GA) GOZETOTIDE , ENZALUTAMIDE
Lacuna Pharma Pty Ltd
Metastatic castration-resistant prostate cancer (mCRPC)
1 trial -
ABO-102, ABO-102, ABO-102
Lacuna Pharma Pty Ltd
Mucopolysaccharidosis type IIIA
1 trial -
AMX0035, PL1 Oral powder in sachet, oral use
Lacuna Pharma Pty Ltd
Amyotrophic Lateral Sclerosis (ALS)
1 trial -
APL-2
Lacuna Pharma Pty Ltd
Geographic Atrophy Secondary to Age-Related Macular Degeneration
1 trial -
ATENATIV 50 UI/mL, poudre et solvant pour solution pour perfusion, Atenativ 1000 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ 1000 I.E. Pulver und Lösungsmittel zur Herstellung einer Infusionslösung, Atenativ 1000 UI/20 ml polvere e solvente per soluzione per infusione endovenosa, Atenativ 50 NE/ml por és oldószer oldatos infúzióhoz vagy injekcióhoz, ATENATIV 1000 U.I., polvo y disolvente para solución para perfusión
Lacuna Pharma Pty Ltd
Congenital antithrombin deficiency
1 trial -
AZACITIDINE, Lisaftoclax, Dummy APG-2575 oral tablets, matching APG-2575 oral tablets. strength: 200 mg/tablet., AZACITIDINE
Lacuna Pharma Pty Ltd
Acute myeloid leukemia
1 trial -
Abemaciclib, Lasofoxifene, Fulvestrant
Lacuna Pharma Pty Ltd
Locally advanced or metastatic breast cancer
1 trial -
Amisulpride, DEXAMETHASONE PHOSPHATE, ONDANSETRON
Lacuna Pharma Pty Ltd
post-operative nausea and vomiting in pediatric patients
1 trial -
An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria
Lacuna Pharma Pty Ltd
Primary Hyperoxaluria
1 trial -
Angoron 150 mg/3 ml amp ενέσιμο διάλυμα, FLECARDIA Διάλυμα για ένεση/έχχυση
Lacuna Pharma Pty Ltd
Cardioversion of paroxysmal atrial fibrillation in the Emergency Department in patients with coronary artery disease without residual ischemia and an left ventricular ejection fraction > 35%
1 trial -
Atenativ 1000 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ, 50 IU/ml, práek a rozpoutědlo pro infuzní roztok, Atenativ 500 I.E. - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung, Atenativ 50 i.e./ml praek in vehikel za raztopino za infundiranje, Atenativ 50 IU/ml prášek a rozpouštědlo pro infuzní roztok, ATENATIV 50 UI/mL, poudre et solvant pour solution pour perfusion, ATENATIV 50 UI/mL, poudre et solvant pour solution p
Lacuna Pharma Pty Ltd
Acquired Antithrombin Deficiency (Heparin Resistance)
1 trial -
Atumelnant 120 mg tablets, Atumelnant 80 mg tablets, Tablet
Lacuna Pharma Pty Ltd
Classic Congenital Adrenal Hyperplasia
1 trial -
Atumelnant 80 mg tablets, Atumelnant 40 mg tablet, Atumelnant 20 mg tablets, Tablet
Lacuna Pharma Pty Ltd
Classic congenital adrenal hyperplasia
1 trial -
Azacitidin Zentiva 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Azacitidine 25 mg/mL powder for suspension for injection, SY-1425, Placebo for Tamibarotene (SY-1425), AZACITIDINE
Lacuna Pharma Pty Ltd
Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome
1 trial -
BRUKINSA 80 mg hard capsules, Calquence 100 mg film-coated tablets, IMBRUVICA 140 mg film-coated tablets, Lisaftoclax, IMBRUVICA 140 mg hard capsules, Lisaftoclax, Calquence 100 mg film-coated tablets, IMBRUVICA 140 mg film-coated tablets, Lisaftoclax, Calquence 100 mg hard capsules, IMBRUVICA 140 mg hard capsules, Calquence 100 mg hard capsules
Lacuna Pharma Pty Ltd
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
1 trial -
Beltavac Polymerized placebo. It is a saline solution without the allergenic extract, BELTAVAC with polymerized extract From Dermatophagoides
Lacuna Pharma Pty Ltd
Allergic rhinoconjunctivitis due to exposure of house dust mites
1 trial -
Berotralstat, Orladeyo 150 mg hard capsules, Berotralstat, Berotralstat, Berotralstat
Lacuna Pharma Pty Ltd
Hereditary Angioedema (HAE)
1 trial -
Betahistine dihydrochloride, BETASERC 24 mg, comprimé
Lacuna Pharma Pty Ltd
Menière's disease
1 trial -
Bexicaserin, LP352 (bexicaserin) Placebo Oral Solution
Lacuna Pharma Pty Ltd
Dravet Syndrome
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources